Comparative evaluation of efficacy of doxycycline incorporated platelet rich fibrin (PRF-D) versus platelet rich fibrin (PRF) alone in the treatment of intrabony defects - A randomized control clinical trial

Periodontal treatment aims at treating the infection caused by pathogenic bacterial biofilm, arresting the progression of disease and reconstituting the structures of the periodontium that are lost, ultimately preventing tooth loss. Regeneration is the ultimate goal of periodontal therapy.

Currently a novel approach to attain periodontal regeneration is the use of Platelet rich fibrin (PRF), that releases polypeptide growth factors (PGFs) which have the ability to regulate cell proliferation, chemotaxis, and differentiation, that may directly contribute to formation of new tissues. PRF is a biomimetic agent which shows favourable results in regeneration of periodontal tissues when used alone or as a combination therapy.

Post-operative microbial colonization can hamper the outcomes of periodontal regenerative therapy. Incorporation of PRF with antibiotics could be a beneficial approach in terms of minimizing the microbial burden and enhancing the results of regenerative procedures.

Doxycycline is proven to be an effective antibiotic against periodontal pathogens and also has an additional benefit of possessing anti-collagenolytic property. Therefore, a combination of platelet rich fibrin and doxycycline can be hypothesized as a promising technique to aid in periodontal regeneration and also to reduce bacterial colonization.